clinical trial · NCT07630727
Study of AHB-171 in Chronic Hepatitis B Participants
Ausper Biopharma Co., Ltd.·phase2·recruiting·n = 138
Hepatitis B, Chronic (CHB)AHB-171 Injection
brief summary
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)
started
Jun 24, 2026
primary completion
Mar 31, 2029
completion
May 31, 2029
last updated
Jul 13, 2026
official title
An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol